December 4th

Data on safety of nine valent HPV vaccine in young people

Two articles in the December 2019 issue of Pediatrics address 9-valent HPV (9vHPV) vaccine safety. In one report from the US Vaccine Adverse Events Reporting System, researchers analyze reports from a 3-year period during which 28 million 9vHPV doses were distributed. In the second report from the Vaccine Safety Datalink, authors describe surveillance for prespecified adverse events after administration of >830 000 9vHPV doses. In both reports, the authors conclude that the post-licensure safety profile of the 9vHPV is consistent with data from the prelicensure trials and that no new safety concerns have been identified.

The 9-valent HPV vaccine is licesnsed for use in the UK however the current vaccination schedule includes the quadrivalent HPV vaccine.

Shimabukoro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6):e20191791 DOI:

Donahue JG, Kieke BA, Lewis EM, et al. Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6):e20191808 DOI:

UK HPV Immunisation Schedule

HPV vaccination is routinely recommended for all girls and boys at 11 to 14 years of age with the first dose offered in school year 8 in England and Wales, S1 in Scotland, and school year 9 in Northern Ireland. The two dose schedule allows flexibility around the schedule with the interval between the first and second dose from 6 months to 24 months (0, 6-24 months) and covers girls and boys from 11 up to and including the age of 14 years. The second dose is therefore offered in school year 8 to 9 in England and Wales, S1 to S3 in Scotland or school year 9 to 10 in Northern Ireland.